CDNAのニュース
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice 2023/01/26 12:01:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monito
Can you still get a good price for CareDx Inc (CDNA) Shares at this point? 2023/01/25 15:48:00 US Post News
A share of CareDx Inc (NASDAQ:CDNA) closed at $15.16 per share on Tuesday, up from $15.05 day before. While CareDx Inc has overperformed by 0.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CDNA fell by -59.06%, with highs and lows ranging from $46.88 to $10.50, […]
CareDx guides for record Q4 revenue 2023/01/09 13:55:49 Seeking Alpha
Precision medicine solutions company CareDx (CDNA) expects record revenues of $81.9M to $82.2M for fourth quarter of 2022, representing year-over-year growth of approximately 4%
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 2023/01/09 12:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter Highlights Delivered record revenues; expected to be between $81.9 million to $82.2 million, representing year-over-year gro
How should investors view CareDx Inc (CDNA)? 2022/12/29 14:16:00 US Post News
CareDx Inc (NASDAQ:CDNA) closed Wednesday at $11.09 per share, up from $10.88 a day earlier. While CareDx Inc has overperformed by 1.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CDNA fell by -74.94%, with highs and lows ranging from $47.82 to $10.68, whereas the simple […]
CareDx Inc (NASDAQ:CDNA) Shares Plunges -3.35% In A Week – But Can It Keep Rising? 2022/11/04 16:00:00 Marketing Sentinel
In recent trading session, CareDx Inc (NASDAQ:CDNA) saw 0.52 million shares changing hands at last check today with its beta currently measuring 1.01. Company’s recent per share price level of $16.51 trading at -$2.22 or -11.85% at last check today assigns it a market valuation of $979.58M. That most recent trading price of CDNA’s stock … CareDx Inc (NASDAQ:CDNA) Shares Plunges -3.35% In A Week – But Can It Keep Rising? Read More »
CareDx, Inc PT Lowered to $32 at Craig-Hallum 2022/11/04 13:32:11 Investing.com
https://www.investing.com/news/pro/caredx-inc-pt-lowered-to-32-at-craighallum-432SI-2933203
CareDx To Participate in Upcoming Investor Conferences 2022/11/04 11:00:00 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx’s management is scheduled to present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9th, 2022, at 1:25 PM ET. To listen
CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2022 Results - Earnings Call Transcript 2022/11/04 02:52:10 Seeking Alpha
CareDx, Inc (NASDAQ:NASDAQ:CDNA) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO…
CareDx, Inc 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2022/11/03 22:13:12 Seeking Alpha
The following slide deck was published by CareDx, Inc in conjunction with their 2022 Q3 earnings call.
CareDx, Inc.: CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society 2022/09/12 12:22:00 Finanz Nachrichten
Over 25 Abstracts Highlight Value of AlloSure and AlloSeq cfDNA CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differ…
CareDx''s Return On Capital Employed Insights 2022/08/17 13:57:48 Benzinga
Benzinga Pro data, CareDx (NASDAQ: CDNA ) reported Q2 sales of $80.63 million. Earnings fell to a loss of $21.70 million, resulting in a 10.43% decrease from last quarter. CareDx collected $79.42 million in revenue during Q1, but reported earnings showed a $19.65 million loss. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
CareDx: Best Near Cap-Gain Health Diagnostics Prospect (NASDAQ:CDNA) 2022/08/08 12:04:04 Seeking Alpha
We discuss why CareDx (CDNA) is now a better buy to help build your portfolio’s near-term capital value. Click here to read more.
CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2022 Results - Earnings Call Transcript 2022/08/07 15:34:01 Seeking Alpha
CareDx, Inc. (NASDAQ:NASDAQ:CDNA) Q2 2022 Results Conference Call August 04, 2022 04:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference…